Fly News Breaks for March 20, 2017
Mar 20, 2017 | 07:46 EDT
Leerink analyst Michael Schmidt notes that Array BioPharma announced it has withdrawn its new drug application for binimetinib in NRAS+ melanoma following recent FDA interactions since results of the Phase 3 trial do not support regulatory approval. While NRAS+ melanoma was only a small value driver for the company, the analyst thinks this comes as a surprise to investors and is "a clear setback" for Array and management's regulatory and commercial strategy. He reiterated a Market Perform rating on the stock, and lowered his price target on the shares to $9 from $11.
News For ARRY From the Last 2 Days
There are no results for your query ARRY